Empowering Mid-size Pharma Companies with Integrated Drug Development

This white paper outlines the challenges and opportunities faced by mid-size pharmaceutical companies in the current market landscape. It describes how these organizations can leverage a consultative, tech-enabled Contract Research Organization (CRO) model to enhance their drug development and regulatory strategies. The paper details the importance of having a flexible and experienced CRO partner that can provide end-to-end services, aligning clinical and regulatory functions with innovative technical solutions. It emphasizes the role of artificial intelligence (AI) in streamlining processes and improving efficiency, enabling mid-size companies to compete effectively with larger firms. Additionally, the white paper presents a case study demonstrating how IQVIA has supported a mid-size client in expanding their clinical development capabilities through dedicated asset development teams. Overall, the document serves as a guide for mid-size pharma companies seeking to optimize their operations and secure a competitive advantage in the industry.